Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis

Basit Öğe Kaydı
dc.authoridKaraer, Abdullah/0000-0002-2010-6211
dc.authoridÇOLAK, CEMİL/0000-0001-5406-098X
dc.authoridGül, Mehmet/0000-0002-1374-0783
dc.authoridAYDIN, Nasuhi/0000-0003-3145-2432
dc.authorwosidAYDIN, Nasuhi Engin/L-1607-2019
dc.authorwosidSimsek, Yavuz/AAH-9894-2021
dc.authorwosidAydin, Nasuhi E/B-6536-2012
dc.authorwosidKaraer, Abdullah/ABI-4667-2020
dc.authorwosidÇOLAK, CEMİL/ABI-3261-2020
dc.authorwosidGül, Mehmet/ABI-6336-2020
dc.authorwosidAYDIN, Nasuhi/O-9043-2016
dc.contributor.authorSimsek, Yavuz
dc.contributor.authorCelik, Onder
dc.contributor.authorKaraer, Abdullah
dc.contributor.authorGul, Mehmet
dc.contributor.authorYilmaz, Ercan
dc.contributor.authorKoc, Onder
dc.contributor.authorColak, Cemil
dc.date.accessioned2024-08-04T20:36:11Z
dc.date.available2024-08-04T20:36:11Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe current study investigated the potential therapeutic efficiency of atosiban, an oxytocin receptor antagonist, in an experimental endometriosis model. Endometriosis was surgically induced in 35 female rats during estrus. Four weeks after this procedure, relaparotomy was performed. The viability and dimensions of the endometriosis foci were recorded. Rats were then randomly divided into three groups. In the first group (n = 8), a daily dose of 0.2 ml 0.9 % NaCl was injected intraperitoneally (i.p.) (control cases). In the second and third groups (n = 8 and n = 8), 0.5 mg/kg/day i.p. atosiban and 1 mg/day i.p. diltiazem were given, respectively. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriosis foci were recorded. The endometrial implants were processed for histological and immunohistochemical studies. The volumes of endometriotic implants were measured, and immunohistochemical analyses were performed, and compared between the groups. After the treatment with atosiban, volumes of endometriotic implants decreased significantly. Proliferating cell nuclear antigen expression levels were significantly reduced in the atosiban and diltiazem groups compared with the control group. In a rat endometriosis model, atosiban, an agent used for the first time for the medical treatment of endometriosis, has shown significant therapeutic efficiency.en_US
dc.identifier.doi10.1007/s00404-012-2390-7
dc.identifier.endpage783en_US
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue3en_US
dc.identifier.pmid22648446en_US
dc.identifier.scopus2-s2.0-84867985507en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage777en_US
dc.identifier.urihttps://doi.org/10.1007/s00404-012-2390-7
dc.identifier.urihttps://hdl.handle.net/11616/95833
dc.identifier.volume286en_US
dc.identifier.wosWOS:000307510200035en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives of Gynecology and Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectReceptorsen_US
dc.subjectOxytocinen_US
dc.subjectAtosibanen_US
dc.subjectTherapyen_US
dc.titleTherapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu